KBC Group
AXSM icon

KBC Group’s Axsome Therapeutics AXSM Stock Holding History

KBC Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$242K Sell
1,311
-856
-40% -$186K ﹤0.01% 952
2026
Q2 		$530K Buy
2,167
+1,046
+93% +$227K ﹤0.01% 792
2026
Q1 		$189K Hold
1,121
– – ﹤0.01% 986
2025
Q4 		$205K Hold
1,121
– – ﹤0.01% 909
2025
Q3 		$136K Hold
1,121
– – ﹤0.01% 1089
2025
Q2 		$117K Sell
1,121
-299
-21% -$31.7K ﹤0.01% 1101
2025
Q1 		$166K Buy
1,420
+84
+6% +$9.6K ﹤0.01% 1171
2024
Q4 		$113K Buy
1,336
+385
+40% +$35.4K ﹤0.01% 1472
2024
Q3 		$85K Hold
951
– – ﹤0.01% 1389
2024
Q2 		$77K Hold
951
– – ﹤0.01% 1330
2024
Q1 		$76K Buy
951
+264
+38% +$22.2K ﹤0.01% 1276
2023
Q4 		$55K Sell
687
-109
-14% -$7.29K ﹤0.01% 1451
2023
Q3 		$56K Buy
+796
New +$59.5K ﹤0.01% 1345

Other funds holding AXSM

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Alethea Capital Management
Alethea Capital Management Mercer Island, Washington $197M AUM 51.86% 1-Year Est. Return

KBC Group's AXSM Position: Q3 2026 in Review

KBC Group reduced its Axsome Therapeutics (AXSM) stake by 40% in Q3 2026, selling an estimated $186K and leaving 1,311 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #952.

KBC Group first reported a position in AXSM in Q3 2023 and has held it in 13 quarters since. The position peaked at $530K in Q2 2026. 348 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • KBC Group held 1,311 shares of Axsome Therapeutics worth $242K as of Q3 2026.
  • KBC Group sold 856 Axsome Therapeutics shares in Q3 2026, an estimated $186K.
  • Axsome Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #952 holding.
  • KBC Group first reported a position in Axsome Therapeutics in Q3 2023 and has held it in 13 quarters since.
  • KBC Group's Axsome Therapeutics position peaked at $530K in Q2 2026.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.